Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study.

Kostikas K, Greulich T, Mackay AJ, Lossi NS, Aalamian-Mattheis M, Nunez X, Pagano VA, Patalano F, Clemens A, Vogelmeier CF.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00243-2018. doi: 10.1183/23120541.00243-2018. eCollection 2019 Feb.

2.

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

3.

Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.

Kostikas K, Aalamian-Mattheis M, Pagano VA, Nunez X, Fogel R, Patalano F, Clemens A.

COPD. 2018 Apr;15(2):185-191. doi: 10.1080/15412555.2018.1445213. Epub 2018 Apr 16. Erratum in: COPD. 2018 Jun;15(3):313.

PMID:
29658810
4.

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators.

Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x.

5.

Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial.

Villoslada P, Rovira A, Montalban X, Arroyo R, Paul F, Meca-Lallana V, Ramo C, Fernandez O, Saiz A, Garcia-Merino A, Ramió-Torrentà L, Casanova B, Oreja-Guevara C, Muñoz D, Martinez-Rodriguez JE, Lensch E, Prieto JM, Meuth SG, Nuñez X, Campás C, Pugliese M; NeuroAdvan study.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 10;2(5):e147. doi: 10.1212/NXI.0000000000000147. eCollection 2015 Oct.

6.

Sulfonamido-aryl ethers as bradykinin B1 receptor antagonists.

Cole AG, Metzger A, Brescia MR, Qin LY, Appell KC, Brain CT, Hallett A, Ganju P, Denholm AA, Wareing JR, Ritchie TJ, Drake GM, Bevan SJ, MacGloinn A, McBryde A, Patel V, Oakley PJ, Nunez X, Gstach H, Schneider P, Baldwin JJ, Dolle RE, McDonald E, Henderson I.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):119-22. doi: 10.1016/j.bmcl.2008.11.005. Epub 2008 Nov 6.

PMID:
19014884
7.

p38 stress-activated protein kinase inhibitor reverses bradykinin B(1) receptor-mediated component of inflammatory hyperalgesia.

Ganju P, Davis A, Patel S, Núñez X, Fox A.

Eur J Pharmacol. 2001 Jun 15;421(3):191-9.

PMID:
11516436
8.

A comparison of the antimutagenic potential of green, black and decaffeinated teas: contribution of flavanols to the antimutagenic effect.

Bu-Abbas A, Nunez X, Clifford MN, Walker R, Ioannides C.

Mutagenesis. 1996 Nov;11(6):597-603.

PMID:
8962430
9.

[Acute glomerulonephritis in children. Prospective study of clinical, histopathologic and immunologic aspects].

Vial S, Donoso P, Rosemberg H, Carranza C, Romero P, Núñez X, Berríos X, Jacobelli S, Foradori A, Cubillos C, et al.

Rev Chil Pediatr. 1987 Jan-Feb;58(1):11-28. Review. Spanish. No abstract available.

PMID:
3327101

Supplemental Content

Support Center